Biologics protect psoriasis patients from being exacerbated by COVID-19 infection.

ABSTRACT:

Background

Patients with psoriasis may experience an exacerbation in symptoms following COVID-19 infection. After abandoning 'zero COVID' strategies, China experienced a surge of Omicron infections.

Objectives

We aimed to investigate psoriasis exacerbation in psoriatic patients with COVID-19, following treatment with three different biologics, adalimumab, secukinumab, and ixekizumab.

Methods

We performed a prospective study (n = 209) at our hospital between November 01, 2022, and February 15, 2023. We defined △ PASI as post-COVID-19 PASI minus pre-COVID-19 PASI. Two endpoints were set in this study. △ PASI >0 was defined as exacerbation of psoriasis after infection. △ PASI >3 was defined as a severe exacerbation of psoriasis symptoms after infection. In addition, seru

SUBMITTER: Zheng YX 

PROVIDER: S-EPMC10828055 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature